What's Happening?
The FDA has initiated a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), with a decision expected by February 2nd next year. The oral formulation of Yeztugo (lenacapavir) aims to expand the options available
for PrEP, complementing Gilead's existing injectable version and daily oral PrEP medicine Descovy. The review is based on the PURPOSE 1 and PURPOSE 2 trials, which demonstrated high efficacy across diverse populations. If approved, Yeztugo could become the first long-acting oral therapy for PrEP, offering more choice for individuals at risk of contracting HIV.
Why It's Important?
The potential approval of Yeztugo as a weekly oral PrEP option represents a significant advancement in HIV prevention strategies. It could provide a more convenient alternative for individuals who prefer not to use injectable therapies, thereby increasing adherence and reducing the risk of HIV transmission. This development underscores Gilead's commitment to innovation in HIV treatment and prevention, potentially impacting public health outcomes by broadening access to effective prevention methods.
What's Next?
If approved, Yeztugo could reshape the landscape of HIV prevention by offering a new long-acting oral option. Gilead is also collaborating with MSD on a once-weekly tablet for treating existing HIV infections, with promising results from recent trials. The company is likely to continue its efforts in developing innovative therapies that address the needs of diverse patient populations, potentially leading to further regulatory filings and market expansions.
